India trying to save vaccines by delaying shots for Covid patients: Government panel

India is trying to save scarce Covid-19 vaccines by delaying shots for those who have recovered from the disease, the head of a government panel said, adding the campaign should not have been opened to all adults before covering the most vulnerable.

Under fire for his handling of the world’s worst rise in coronavirus infections, Prime Minister Narendra Modi made all adults eligible for vaccination from May 1.

Vaccine shortages have now forced many regions, including the capital New Delhi, to again prioritise those aged above 45.

The federal government on Wednesday said patients should go for their vaccination three months after recovery, compared with the earlier recommendation of about one month. It did not give a reason.

“It’s been done to save vaccine doses,” Narendra Kumar Arora, head of the government’s National Technical Advisory Group on Immunisation, told Reuters on Friday. “We discussed delaying it by three months, six months or nine months, but finally we said ‘we can manage it with three months, let’s do three months for now'”.

Arora said that given the vaccine shortage in India, the focus should have been on immunising the most at risk.

“Our group prioritised those aged 45 or more,” he said. “Because 75% of the mortality and morbidity is in that age group.”

The Ministry of Health and Family Welfare said on April 19 that the decision to include all adults in the immunisation campaign was taken in a meeting chaired by Modi.

The ministry and Modi’s office did not respond to a request for comment.

India has administered about 192 million doses, the most after China and the United States, but given the necessary two doses to only about 3% of its 1.35 billion people.

  • Related Posts

    • Pharma
    • July 11, 2025
    • 70 views
    India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

    July:  India’s Glenmark Pharmaceuticals (GLEN.NS), opens new tab said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie (ABBV.N), opens new tab have signed an exclusive licensing agreement…

    • Pharma
    • July 10, 2025
    • 140 views
    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

    India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Novartis wins approval for first malaria drug for newborns and babies

    Novartis wins approval for first malaria drug for newborns and babies